April 9, 2019
Concerto HealthAI, the maker of a clinical insight generation platform that employs real-world data in its analyses, is racking up the pharma partnerships as of late. Just weeks after the artificial intelligence company agreed to a multi-year deal with Bristol-Myers Squibb, Concerto announced this morning a similar project with Pfizer that will support the latter’s research on precision oncology...
Inside the wearable device, the blood pump sits in the upper left corner while the heparin injector runs the length of the near side of the box. The green circuit boards control the blood pump, heparin injector and provide display data. Photo Credit: Tae Hyun Kim
April 1, 2019
In an open Nature Communications paper published today, researchers from the University of Michigan described a prototype wearable device that could continuously collect bloodborne cancer cells often used as a biomarker for treatment.
Currently, blood draws are required to identify and examine circulating tumor cells (CTCs), and are often limited by inconsistent CTC counts as well as the health...
Photo: Dr. James Creeden, Global Medical Director of Foundation Medicine. Credit: Foundation Medicine.
January 10, 2019
Launched in 2010 with a $25 million Series A financing led by Third Rock Ventures, Foundation Medicine released its first commercial assay called FoundationOne in 2012. The company develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumours, hematologic malignancies, and sarcomas. In December 2017, the company’s assay FoundationOne...
Credit: Foundation Medicine
November 29, 2018
Roche announced last week the launch of FoundationOne CDx, Foundation Medicine’s comprehensive companion diagnostic test for personalised cancer care in Singapore. According to the official media release, FoundationOne CDx supports clinicians in their decision-making by providing a clear, in-depth report that describes the unique genomic profile of a patient’s tumour as well as associated,...
July 19, 2018
The Department of Veterans Affairs and IBM Watson Health have announced a one-year extension to an ongoing public-private partnership applying the AI company’s technology to genomic data for cancer therapy.
The precision oncology collaboration has so far assisted the treatment of more than 2,700 veterans, according to a statement, although the original agreement in 2016 had proposed the lofty...